GeoVax Labs Inc. (NASDAQ: GOVX)
$2.96
+0.1500 ( +5.34% ) 4.0M
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy againstĀ head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.
Market Data
Open
$2.96
Previous close
$2.81
Volume
4.0M
Market cap
$7.48M
Day range
$2.82 - $3.55
52 week range
$1.09 - $10.24
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 25 | Jul 12, 2024 |
8-k | 8K-related | 15 | Jun 21, 2024 |
8-k | 8K-related | 16 | Jun 18, 2024 |
8-k | 8K-related | 14 | May 24, 2024 |
8-k | 8K-related | 15 | May 23, 2024 |
8-k | 8K-related | 25 | May 21, 2024 |
8-k | 8K-related | 16 | May 15, 2024 |
10-q | Quarterly Reports | 48 | May 14, 2024 |
def | Proxies and info statements | 5 | Apr 15, 2024 |
pre | Proxies and info statements | 5 | Apr 03, 2024 |